Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | ACHE | P22303 | 4/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267102 | 1.00 | DRD2 (1.00) | DRD2DRD3ACHEDRD4MTNR1A | |
| SCHEMBL354006 | 1.00 | DRD2 (1.00) | DRD2DRD3ACHEDRD4MTNR1A | |
| Hydrochloric Acid SCHEMBL6400112 | 0.98 | DRD2 (0.97) | DRD2DRD3ACHEDRD4MTNR1A | |
| Hydrochloric Acid SCHEMBL3001108 | 0.98 | DRD2 (0.97) | DRD2DRD3ACHEDRD4MTNR1A | |
| Hydrochloric Acid SCHEMBL5216725 | 0.98 | DRD2 (0.97) | DRD2DRD3ACHEDRD4MTNR1A | |
| SCHEMBL19900934 | 0.93 | DRD2 (0.87) | DRD2DRD3ACHECA1CA2 | |
| SCHEMBL264631 | 0.93 | DRD2 (0.87) | DRD2DRD3ACHECA1CA2 | |
| SCHEMBL30416676 | 0.93 | DRD2 (0.87) | DRD2DRD3ACHECA1CA2 | |
| Hydrochloric Acid SCHEMBL2991649 | 0.92 | DRD2 (0.84) | DRD2DRD3ACHECA1CA2 | |
| Hydrochloric Acid SCHEMBL30298163 | 0.92 | DRD2 (0.84) | DRD2DRD3ACHECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684953-B1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORP (JP) | 2017-06-28 | — | — | EP | claimed |
| US-9029113-B2 | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same | KANEKA CORPORATION (JP) | 2015-05-12 | — | — | US | claimed |
| EP-2684953-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | Kaneka Corporation (JP) | 2014-01-15 | — | — | EP | claimed |
| US-20140004575-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORPORATION (JP) | 2014-01-02 | — | — | US | claimed |
| EP-2022852-B1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE AMINE COMPOUND, RECOMBINANT VECTOR, AND TRANSFORMANT CARRYING THE VECTOR | KANEKA CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-2684953-B1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORP (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9029113-B2 | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same | KANEKA CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2684953-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | Kaneka Corporation (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20140004575-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORPORATION (JP) | 2014-01-02 | — | — | US | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8168412-B2 | Method for producing optically-active amine compound, recombinant vector, and transformant containing the vector | KANEKA CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-7172885-B2 | Contacting chiral primary amine, omega-transaminase, and amino acceptor to convert into ketone; stereospecific; gene expression | CAMBREX NORTH BRUNSWICK, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060228788-A1 | Thermostable omega-transaminases | CAMBRED KARLSKOGA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| WO-2006063336-A2 | THERMOSTABLE OMEGA-TRANSAMINASES | CAMBREX NORTH BRUNSWICK, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20050153408-A1 | 7-substituted-2-tetralone or bisulfite adduct is reduced microorganism (Candida) to optically active 7-substituted-2-tetralol;sulfonyl group is introduced to hydroxy group to form optically active 7-substituted-2-sulfonyloxytetralin; nitrogen substituent is introduced via ammonia; industrial scale | KANEKA CORPORATION (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1457570-A1 | PROCESS FOR PREPARATION OF 2-AMINOTETRALIN DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-0683236-B1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI SYNTHELABO (FR) | 2000-08-09 | — | — | EP | disclosed |
| EP-0683236-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI (FR) | 1995-11-22 | — | — | EP | disclosed |
| EP-0678579-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | MIDY S.p.A. (IT) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228788-A1 | Thermostable omega-transaminases | FADS2, SCD, CES1 | DRD2 1361/4885DRD3 1701/4885ACHE 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.